Joji Suzuki MD
Addiction, Psychosomatic Medicine
Associate Professor of Psychiatry, Harvard Medical School; Director, Division of Addiction Psychiatry, Brigham and Women's Hospital
Join to View Full Profile
60 Fenwood RdBoston, MA 02115
Phone+1 617-732-5752
Fax+1 617-738-1275
Dr. Suzuki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston University Medical CenterFellowship, Addiction Psychiatry, 2006 - 2007
Maine Medical CenterResidency, Psychiatry, 2002 - 2006
Boston University School of MedicineClass of 2002
Certifications & Licensure
MA State Medical License 2006 - 2025
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Addiction Psychiatry
American Board of Preventive Medicine Addiction Medicine
Publications & Presentations
PubMed
- A network perspective on heroin use: associations between craving, withdrawal symptoms, dependence, loss of control, and psychosocial consequences.Veronica Szpak, Joji Suzuki, Reinout W Wiers, René Freichel
Addictive Behaviors. 2025-10-01 - Alcohol-related encounter surveillance using emergency medical service records in Massachusetts, 2013-2023.Amy Bettano, Ridgely Ficks, Gerard Gonzales, Matthew Blackburn, Joji Suzuki
Drug and Alcohol Dependence. 2025-08-06 - Oral cavity cancer after sublingual buprenorphine use.Annie R Abruzzo, Miriam T H Harris, Herve Y Sroussi, Joji Suzuki, Jason I Kass
Oral Oncology. 2025-08-05
Press Mentions
Hype or Hope? Latest Research on GLP-1 Receptor Agonists and AddictionMay 6th, 2025- Alcohol-Related Mortality up Sharply During PandemicNovember 9th, 2022
- Sifting the Damage of Pandemic-Era DrinkingJune 14th, 2022
- Join now to see all
Grant Support
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Extended release buprenorphine as a novel low-dose induction strategyBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Extended release buprenorphine as a novel low-dose induction strategyBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Extended release buprenorphine as a novel low-dose induction strategyBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Extended release buprenorphine as a novel low-dose induction strategyBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Extended release buprenorphine as a novel low-dose induction strategyBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialBRIGHAM AND WOMEN'S HOSPITAL2024–2026
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Oral complications from sublingual buprenorphine treatment: A prospective cohort studyBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency departmentBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Developing and pilot testing a novel remotely delivered intensive outpatient program for individuals with opioid use disorder hospitalized with serious injection-related infectionsBRIGHAM AND WOMEN'S HOSPITAL2022–2025
- Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trialBRIGHAM AND WOMEN'S HOSPITAL2022–2025
Professional Memberships
- American Academy of Addiction PsychiatryMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
